Table 5.

Mean pharmacokinetic parameters of S-1 analytes on day 42 following repeated twice daily oral administration of S-1 for two weeks

S-1 analyte
	5-FU		CDHP		Tegafur		Oteracil
	Aflibercept dose level
Mean ± SD	2 mg/kg	4 mg/kga	2 mg/kg	4 mg/kga	2 mg/kg	4 mg/kga	2 mg/kg	4 mg/kga
Number of patients	7	1	7	1	7	1	7	1
Cmax, ng/mL	130 ± 35.0	104	367 ± 138	266	4730 ± 1840	4670	53.5 ± 38.7	29.5
Tmaxb, h	2.00 (1.97–2.05)	3.95	1.05 (0.97–2.05)	1.97	1.05 (0.92–2.05)	1.97	1.97 (0.97–2.05)	3.95
AUCτ, ng·h/mL	912 ± 174c	654	1650 ± 540e	1320	41,600 ± 19,500	47,100	306 ± 269g	226
AUClast, ng·h/mL	788c ± 370	817	1820e ± 825	1730	91,400 ± 52,600	113,000	378g ± 390	466
t1/2z, h	3.66 ± 0.0225d	3.87	3.63 ± 1.13f	9.2	15.7 ± 4.26	19.6	5.72 ± 3.48h	19.6

CDHP, gimeracil; 5-FU, 5-fluorouracil; SD, standard deviation. PK parameters reported are: AUC_last area under the concentration versus time curve (AUC) from time 0 to the real time t_last; AUC_τ, AUC from time 0 to the end of the dosing period; C_max, maximum drug concentration observed; t_1/2z, terminal half-life; T_max, first time to reach C_max

^an = 1, individual values listed

^bMedian (range)

^cn = 3, 4 patients were not included in the calculation of summary statistics

^dn = 2, 5 patients were not included in the calculation of summary statistics

^en = 6, 1 patient was not included in the calculation of summary statistics

^fn = 4, 3 patients were not included in the calculation of summary statistics

^gn = 6, 1 patient was not included in the calculation of summary statistics

^hn = 4, 3 patients were not included in the calculation of summary statistics

Profile of 1 patient was excluded for 5-FU, CDHP, tegafur and oteracil